Publications
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F, National Comprehensive Cancer Network. Non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN. 2008. PMID: 18433606
Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Seminars in oncology. 2008. PMID: 18410794
Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. The Journal of clinical investigation. 2008. PMID: 18382737
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Investigational new drugs. 2008. PMID: 18379729
Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs of today (Barcelona, Spain : 1998). 2008. PMID: 18536785
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Investigational new drugs. 2008. PMID: 18379729
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Investigational new drugs. 2008. PMID: 18379729
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Investigational new drugs. 2008. PMID: 18379729
Pearson HB, McCarthy A, Collins CM, Ashworth A, Clarke AR. Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer research. 2008. PMID: 18381428
Smalley MJ, Reis-Filho JS, Ashworth A. BRCA1 and stem cells: tumour typecasting. Nature cell biology. 2008. PMID: 18379596
Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Seminars in oncology. 2008. PMID: 18410794
Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. PMID: 18347007
Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Current opinion in genetics & development. 2008. PMID: 18343102
Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Laboratory investigation; a journal of technical methods and pathology. 2008. PMID: 18332872
Keys JR, Tallack MR, Zhan Y, Papathanasiou P, Goodnow CC, Gaensler KM, Crossley M, Dekker J, Perkins AC. A mechanism for Ikaros regulation of human globin gene switching. British journal of haematology. 2008. PMID: 18318763
Shah NP. Advanced CML: therapeutic options for patients in accelerated and blast phases. Journal of the National Comprehensive Cancer Network : JNCCN. 2008. PMID: 18397679
Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2008. PMID: 18377844
Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC. Small cell lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2008. PMID: 18377848
Choo SP, Venook AP. Responding to the rising incidence of hepatocellular carcinoma with targeted therapy. Gastrointestinal cancer research : GCR. 2008. PMID: 19259302
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. PMID: 18309951